TDAC

+ Watchlist + Portfolio

Translational Development Acquisition Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.85
52-Week Range: $10.32 – $10.95
Market Cap: $209.31M
P/E (TTM): 41.69
EPS (TTM): 0.26
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -0.49%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.06
Debt/Equity: —
Total Debt: $1.10M
Free Cash Flow: $-355.05K
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $238.60M

TDAC Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Selling, General & Admin	$485.55K	$196.36K	$944.54K
Operating Expenses	$485.55K	$196.36K	$944.54K
Operating Income	-$485.55K	-$196.36K	-$944.54K
EBITDA	-$485.55K	-$196.36K	-$944.54K
Pretax Income	-$485.55K	-$71.01K	$6.36M
Net Income	-$485.55K	-$71.01K	$6.36M
Diluted EPS	-0.11	-0.02	0.29
Diluted Shares	19.05M	19.05M	21.91M

TDAC Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$204.00	-$851.45K	-$608.39K
Free Cash Flow	-$204.00	-$851.45K	-$608.39K
Investing Cash Flow	$0.00	-$174.22M	$0.00
Financing Cash Flow	$0.00	$175.51M	$200.00K
Net Change in Cash	-$204.00	$436.15K	-$408.39K

TDAC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Selling, General & Admin	$347.41K	$221.13K	$213.66K	$162.34K	$281.16K
Operating Expenses	$347.41K	$221.13K	$213.66K	$162.34K	$281.16K
Operating Income	-$347.41K	-$221.13K	-$213.66K	-$162.34K	-$281.16K
EBITDA	-$347.41K	-$221.13K	-$213.66K	-$162.34K	-$281.16K
Pretax Income	$1.48M	$1.62M	$1.66M	$1.60M	$1.33M
Net Income	$1.48M	$1.62M	$1.66M	$1.60M	$1.33M
Diluted EPS	0.07	0.07	0.08	—	0.06
Diluted Shares	21.91M	21.91M	21.91M	—	21.91M

TDAC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$206.60K	$35.26K	$47.15K	$29.79K	$24.63K
Current Assets	$415.42K	$156.08K	$80.58K	$39.47K	$75.32K
Total Assets	$176.60M	$178.18M	$179.98M	$181.70M	$183.35M
Current Liabilities	$322.90K	$284.68K	$422.85K	$544.07K	$861.09K
Total Debt	—	—	$100.00K	$200.00K	$500.00K
Total Liabilities	$6.36M	$6.32M	$6.46M	$6.58M	$6.90M
Retained Earnings	-$5.95M	-$6.17M	-$6.38M	-$6.54M	-$6.82M
Shareholders' Equity	$170.24M	$171.86M	$173.52M	$175.12M	$176.45M
Working Capital	$92.52K	-$128.60K	-$342.26K	-$504.61K	-$785.77K
Net Debt	—	—	$52.85K	$170.21K	$475.37K

TDAC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$231.57K	-$171.34K	-$88.11K	-$117.36K	-$305.16K
Free Cash Flow	-$231.57K	-$171.34K	-$88.11K	-$117.36K	-$305.16K
Financing Cash Flow	$0.00	$0.00	$100.00K	$100.00K	$300.00K
Net Change in Cash	-$231.57K	-$171.34K	$11.89K	-$17.36K	-$5.16K

Market Snapshot

About

Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) formed to effect a merger, capital stock exchange, asset acquisition, or similar business combination. The SPAC targets businesses in the healthcare and life sciences sectors, particularly those focused on translational medicine and innovative therapies. TDAC seeks to identify and partner with companies that can benefit from public market access and growth capital.